Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Enzalutamide (Primary) ; Olaparib (Primary) ; Pembrolizumab (Primary) ; Pembrolizumab+vibostolimab (Primary) ; Abiraterone acetate; Belzutifan; Carboplatin; Dexamethasone; Docetaxel; Etoposide; Lenvatinib; Prednisone; Vibostolimab
- Indications Adenocarcinoma; Neuroendocrine carcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-365
- Sponsors Merck Sharp & Dohme Corp.
- 27 Jan 2024 Trial designof pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (Cohort J) presented at the 2024 Genitourinary Cancers Symposium
- 27 Jan 2024 Trial design presented at the 2024 Genitourinary Cancers Symposium
- 27 Jan 2024 Results from cohort E, analyzing safety and efficacy of pembro + lenva was evaluated in pts with docetaxel-pretreated mCRPC, presented at the 2024 Genitourinary Cancers Symposium